Respiratory Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Application, By End User, By Region and Competition, 2020-2030F

Description

Global Respiratory Disease Testing Market was valued at USD 6.01 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.72% through 2030F. Respiratory diagnostics involve the clinical assessment of lung function and related respiratory processes to identify and manage various pulmonary conditions. These diagnostics play a vital role in detecting disorders such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, bronchitis, and pulmonary fibrosis.A broad spectrum of tools and techniques is used in respiratory diagnostics, encompassing mechanical, imaging, and molecular testing approaches. Common procedures include spirometry, which measures airflow and lung volumes to assess obstructive and restrictive lung diseases, and oximetry, which evaluates blood oxygen saturation levels.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.01 Billion
Market Size 2030	USD 8.32 Billion
CAGR 2025-2030	5.72%
Fastest Growing Segment	Imaging Tests
Largest Market	North America

Transcutaneous carbon dioxide (CO2) monitoring is used to measure CO2 levels in the blood through the skin, helping clinicians assess respiratory efficiency. Another technique, sniff nasal inspiratory pressure (SNIP), is employed to evaluate inspiratory muscle strength, especially in patients with neuromuscular disorders. Imaging methods such as chest X-rays and computed tomography (CT) scans are crucial for visualizing lung structure, identifying tumors, infections, or fibrosis, and guiding further interventions. These imaging tools provide detailed information that supports accurate diagnosis and treatment planning. In specific cases, sleep studies are conducted to diagnose conditions like obstructive sleep apnea and nocturnal hypoventilation, especially in patients exhibiting symptoms such as daytime fatigue, loud snoring, or interrupted breathing during sleep. These studies monitor breathing patterns, oxygen levels, and other physiological functions during sleep. The respiratory diagnostics are essential for early detection, monitoring, and management of pulmonary diseases. They not only facilitate timely intervention but also help in tailoring treatment strategies based on the individual patient's respiratory profile, thereby improving clinical outcomes and quality of life.

Key Market Drivers

Growing Burden of Respiratory Diseases

The increasing prevalence of respiratory diseases is a significant driver for market growth. For instance, according to a 2023 article, Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition linked to serious complications such as cardiovascular disease, respiratory failure, and lung cancer. Key risk factors include smoking, air pollution (indoor and outdoor), genetic predisposition, occupational exposures, and infections during childhood or adulthood. Factors such as the rise in smokers, alcohol consumption, sedentary lifestyle habits, and stressful routines have led to an increase in cases of COPD and other severe respiratory conditions, including lung cancer. The technological advancements in respiratory diagnostic testing, such as the utilization of Internet of Things (IoT) and Artificial Intelligence (AI) for COPD diagnosis and outpatient management, have positively impacted market growth. The growing demand for respiratory diagnostics devices in privately-owned hospitals and healthcare centers, along with the efforts of government and non-governmental organizations (NGOs) to improve access to quality healthcare facilities, are key drivers of the respiratory diagnostics market. Respiratory symptoms rank among the primary reasons for seeking medical consultation in primary healthcare centers. Key preventable chronic respiratory disorders include asthma, COPD, allergic rhinitis, sleep apnea, and tuberculosis (particularly multi-drug resistant tuberculosis). As of September 2022, the CDC reported 873,000 emergency department visits for COPD in the United States in 2020, with 5% of adults receiving a new diagnosis of COPD, emphysema, or chronic bronchitis. These statistics underscore the growing burden of respiratory diseases on society, which is expected to drive the demand for respiratory disease testing and fuel market growth.

Key Market Challenges

High Cost and Lack of Skilled Professionals

The significant cost associated with diagnostic procedures poses a major challenge to the growth of the global respiratory diagnostics market during the forecast period. The rapid technological advancements in the field have led to a shortage of qualified specialists. The lack of competent experts has greatly hindered the proper handling of instruments and the execution of procedures. The cost associated with setting up and maintaining advanced respiratory disease testing facilities, including purchasing equipment, reagents, and maintaining quality control, can be substantial. This cost burden can discourage healthcare providers from investing in the necessary infrastructure. The high cost of establishing and operating testing facilities can lead to geographic disparities in access. Remote or underserved areas may lack the resources needed to offer comprehensive respiratory disease testing, limiting access for vulnerable populations. The specialized nature of respiratory disease testing requires trained and skilled laboratory professionals who can operate and interpret complex diagnostic equipment accurately. A shortage of such professionals can lead to delays in testing, misinterpretation of results, and overall reduced testing capacity.

Key Market Trends

Point-of-Care Testing (POCT) Expansion

The expansion of point-of-care testing for respiratory diseases will enable rapid and convenient testing in various healthcare settings, such as clinics, pharmacies, and community health centers. POCT devices will facilitate timely diagnosis and monitoring, especially in resource-limited environments. POCT devices provide rapid results, often within minutes, allowing healthcare providers to make timely decisions about patient care. In cases of acute respiratory conditions, such as respiratory infections or exacerbations of chronic diseases, quick diagnosis can lead to immediate initiation of appropriate treatment. Traditional laboratory testing involves transporting samples, processing, and result reporting, which can lead to delays.

POCT devices minimize turnaround time, enabling healthcare providers to quickly assess a patient's respiratory status and make informed decisions without waiting for external laboratory results. As technology continues to advance, the development of accurate, user-friendly, and affordable POCT devices for respiratory diseases has the potential to revolutionize healthcare delivery, particularly in settings where access to traditional laboratory testing is limited. It empowers healthcare providers with actionable information and empowers patients to actively manage their respiratory health, contributing to better overall healthcare outcomes.

Key Market Players

Beckton Dickinson and Company
Koninklijke Philips N.V.
ResMed Inc.
Medtronic PLC
Carestream Health Inc.
MG Diagnostic Corporation
Abbott Laboratories Ltd.
ThermoFisher Scientific Inc.
Biomerieux Inc.
QIAGEN NV

Report Scope:

In this report, the Global Respiratory Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Disease Testing Market, By Test Type:

Imaging Tests
Mechanical Tests
In-vitro Diagnostic Tests

Respiratory Disease Testing Market, By Application:

COPD
Lung Cancer
Asthma
Tuberculosis

Respiratory Disease Testing Market, By End User:

Hospitals
Diagnostic Centres
Others

Respiratory Disease Testing Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Testing Market.

Available Customizations:

Global Respiratory Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Disease Testing Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests)
- 5.2.2. By Application (COPD, Lung Cancer, Asthma, Tuberculosis)
- 5.2.3. By End User (Hospitals, Diagnostic Centers, and Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Respiratory Disease Testing Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By Application
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Respiratory Disease Testing Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Respiratory Disease Testing Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Respiratory Disease Testing Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By End User

7. Europe Respiratory Disease Testing Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By Application
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Respiratory Disease Testing Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By End User
- 7.3.2. United Kingdom Respiratory Disease Testing Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By End User
- 7.3.3. Italy Respiratory Disease Testing Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Test Type
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By End User
- 7.3.4. France Respiratory Disease Testing Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Respiratory Disease Testing Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By End User

8. Asia-Pacific Respiratory Disease Testing Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By Application
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Respiratory Disease Testing Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By End User
- 8.3.2. India Respiratory Disease Testing Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Respiratory Disease Testing Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Respiratory Disease Testing Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Respiratory Disease Testing Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By End User

9. South America Respiratory Disease Testing Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type
- 9.2.2. By Application
- 9.2.3. By End User
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Respiratory Disease Testing Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By End User
- 9.3.2. Argentina Respiratory Disease Testing Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By End User
- 9.3.3. Colombia Respiratory Disease Testing Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By End User

10. Middle East and Africa Respiratory Disease Testing Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type
- 10.2.2. By Application
- 10.2.3. By End User
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Respiratory Disease Testing Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Respiratory Disease Testing Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By End User
- 10.3.3. UAE Respiratory Disease Testing Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

13. Global Respiratory Disease Testing Market: SWOT Analysis

14. Competitive Landscape

14.1. Beckton Dickinson and Company
- 14.1.1. Business Overview
- 14.1.2. Services Offerings
- 14.1.3. Recent Developments
- 14.1.4. Key Personnel
- 14.1.5. SWOT Analysis
14.2. Koninklijke Philips N.V.
14.3. ResMed Inc.
14.4. Medtronic PLC
14.5. Carestream Health Inc.
14.6. MG Diagnostic Corporation
14.7. Abbott Laboratories Ltd.
14.8. ThermoFisher Scientific Inc.
14.9. Biomerieux Inc.
14.10. QIAGEN NV